Workflow
navacaprant
icon
Search documents
Neumora Therapeutics to Host Virtual R&D Day on October 27
Globenewswire· 2025-10-01 11:00
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&D Day on Monday, October 27, 2025, at 8:00 a.m. ET. Neumora is advancing a robust pipeline of novel mechanisms of action that each have the potential to fundamentally c ...
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Globenewswire· 2025-08-06 20:05
Core Insights - Neumora Therapeutics has initiated a Phase 1 single-ascending dose/multiple-ascending dose study for NMRA-861, with data expected in Q1 2026 [1][4] - The company has prioritized obesity as the lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from preclinical studies expected in 2025 [1][6][7] - Neumora is entering a catalyst-rich period with up to six clinical data readouts anticipated over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder and Phase 1b data for NMRA-511 in Alzheimer's disease agitation [1][3][8][9] - The company reported a strong financial position with $217.6 million in cash, cash equivalents, and marketable securities, expected to support operations into 2027 [1][14] Pipeline Highlights - NMRA-861, an M4 positive allosteric modulator, has entered Phase 1 clinical studies targeting schizophrenia and other neuropsychiatric disorders [4][5] - NMRA-215 has shown potential for best-in-class brain penetration and is being developed for obesity, with clinical studies expected to start in Q1 2026 [6][7] - Navacaprant is currently in Phase 3 trials for major depressive disorder, with topline data expected in the first half of 2026 [8] - NMRA-511 is on track to report data from a Phase 1b study for Alzheimer's disease agitation by the end of 2025 [9] Financial Overview - For Q2 2025, Neumora reported research and development expenses of $38.7 million, down from $48.6 million in the same period of 2024, primarily due to reduced stock-based compensation and clinical trial costs [14][16] - General and administrative expenses for Q2 2025 were $15.3 million, slightly up from $15.2 million in Q2 2024 [14][16] - The net loss for Q2 2025 was $52.7 million, compared to a net loss of $58.7 million in Q2 2024 [14][16]
JNJ Halts Development of Depression Drug Over Efficacy Concerns
ZACKS· 2025-03-07 18:45
Core Viewpoint - Johnson & Johnson (J&J) has decided to discontinue the Phase 3 VENTURA development program for aticaprant as an adjunctive treatment for major depressive disorder (MDD) due to insufficient efficacy in the target patient population, despite the drug being safe and well-tolerated [1][2][3]. Group 1: Development Program and Financial Implications - The decision to halt the VENTURA program is a setback for J&J, which had anticipated annual peak sales of $1-$5 billion from aticaprant in the MDD indication [3]. - J&J is currently conducting full analyses of the VENTURA program data and plans to present findings at a future medical meeting [2]. Group 2: Future Plans and Acquisitions - Despite the setback, J&J maintains its long-term vision to become the 1 neuroscience company by 2030 and expects its Innovative Medicine business to grow at a CAGR of 5% to 7% from 2025 to 2030 [4]. - The company aims to offset the loss from aticaprant with the acquisition of Intra-Cellular Therapies (ITCI) for approximately $14.6 billion, which is expected to be completed later this year [5]. - Upon completion of the acquisition, J&J will gain access to ITCI's marketed drug, Caplyta, which is approved for schizophrenia and bipolar depression, with a regulatory filing submitted for label expansion to include MDD [6]. Group 3: Market Performance - Year to date, J&J's shares have increased nearly 15%, outperforming the industry growth of 12% [7]. Group 4: Industry Context - The setback with aticaprant is not isolated, as Neumora Therapeutics also faced a failure with its lead drug, navacaprant, in a similar MDD study [9]. - Neumora's KOASTAL-1 study did not achieve its primary endpoint, failing to show significant improvement over placebo in alleviating depression symptoms [10].
Neumora Therapeutics(NMRA) - 2024 Q4 - Earnings Call Transcript
2025-03-03 16:37
Financial Data and Key Metrics Changes - Total operating expenses for Q4 2024 were $58.8 million, down from $108.7 million in Q4 2023, while full-year operating expenses increased slightly to $243.8 million from $235.9 million in 2023 [32] - As of December 31, 2024, the company had $307.6 million in cash, cash equivalents, and marketable securities, expected to support operations into mid-2026 [33] Business Line Data and Key Metrics Changes - The company is advancing navacaprant, currently in Phase 3 development for MDD, and has made changes to optimize ongoing studies based on learnings from the KOASTAL-1 study [11][12] - NMRA-511 is being investigated in a Phase 1b study for Alzheimer's disease agitation, with top-line data expected by the end of 2025 [15][17] Market Data and Key Metrics Changes - Approximately 70% of the estimated 7 million people living with Alzheimer's disease experience agitation, indicating a significant unmet need in this market [16] Company Strategy and Development Direction - The company aims to deliver transformative medicines for brain diseases, focusing on a pipeline of seven programs targeting novel mechanisms of action [7] - The strategy for the KOASTAL program includes enhancing patient monitoring and site selection to improve study outcomes [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of navacaprant despite previous study results, citing a strong pipeline and a commitment to addressing unmet needs in brain disease treatment [19][31] - The company is focused on disciplined capital allocation to leverage its strong balance sheet for future catalysts across its programs [32] Other Important Information - The company has discontinued the Phase 2 trial for navacaprant in bipolar depression to prioritize resources for the KOASTAL program [14] - The company is advancing four preclinical programs targeting various brain disorders, including Alzheimer's agitation and schizophrenia [29] Q&A Session Summary Question: Differences between KOASTAL-1 vendor and SAFER - The company is enhancing medical monitoring to confirm patient diagnoses and is partnering with Mass General Hospital's SAFER for independent reviews [37][39] Question: Enrollment status of KOASTAL-2 and 3 - The company is not disclosing specific enrollment numbers but is optimistic about the changes made to improve outcomes in these studies [51] Question: Placebo response in KOASTAL-1 - The company identified that site experience significantly impacted performance, particularly in male patients, and is focusing on site selection for future studies [46][48] Question: Cash runway and financing strategies - The company maintains a strong financial position and is exploring various funding mechanisms to support operations [66][70] Question: Interim analysis for KOASTAL studies - No interim analysis is planned for KOASTAL-2 and 3 due to the short duration of the studies [87] Question: Update on NMRA-266 clinical hold - The company is working to determine the path forward for NMRA-266 while progressing follow-on compounds in the M4 franchise [92]